Analysis of Gene Expression in the Normal and Malignant Cerebellum
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Detection of Interacting Transcription Factors in Human Tissues Using
Myšičková and Vingron BMC Genomics 2012, 13(Suppl 1):S2 http://www.biomedcentral.com/1471-2164/13/S1/S2 PROCEEDINGS Open Access Detection of interacting transcription factors in human tissues using predicted DNA binding affinity Alena Myšičková*, Martin Vingron From The Tenth Asia Pacific Bioinformatics Conference (APBC 2012) Melbourne, Australia. 17-19 January 2012 Abstract Background: Tissue-specific gene expression is generally regulated by combinatorial interactions among transcription factors (TFs) which bind to the DNA. Despite this known fact, previous discoveries of the mechanism that controls gene expression usually consider only a single TF. Results: We provide a prediction of interacting TFs in 22 human tissues based on their DNA-binding affinity in promoter regions. We analyze all possible pairs of 130 vertebrate TFs from the JASPAR database. First, all human promoter regions are scanned for single TF-DNA binding affinities with TRAP and for each TF a ranked list of all promoters ordered by the binding affinity is created. We then study the similarity of the ranked lists and detect candidates for TF-TF interaction by applying a partial independence test for multiway contingency tables. Our candidates are validated by both known protein-protein interactions (PPIs) and known gene regulation mechanisms in the selected tissue. We find that the known PPIs are significantly enriched in the groups of our predicted TF-TF interactions (2 and 7 times more common than expected by chance). In addition, the predicted interacting TFs for studied tissues (liver, muscle, hematopoietic stem cell) are supported in literature to be active regulators or to be expressed in the corresponding tissue. -
Conservation of Topology, but Not Conformation, of the Proteolipid Proteins of the Myelin Sheath
The Journal of Neuroscience, January 1, 1997, 17(1):181–189 Conservation of Topology, But Not Conformation, of the Proteolipid Proteins of the Myelin Sheath Alexander Gow,1 Alexander Gragerov,1 Anthony Gard,2 David R. Colman,1 and Robert A. Lazzarini1 1Brookdale Center for Molecular Biology, Mount Sinai School of Medicine, New York, New York 10029-6574, and 2Department of Structural and Cell Biology, University of South Alabama College of Medicine, Mobile, Alabama 36688 The proteolipid protein gene products DM-20 and PLP are during de novo synthesis. Surprisingly, the conformation (as adhesive intrinsic membrane proteins that make up $50% of opposed to topology) of DM-20 and PLP may differ, which has the protein in myelin and serve to stabilize compact myelin been inferred from the divergent effects that many missense sheaths at the extracellular surfaces of apposed membrane mutations have on the intracellular trafficking of these two lamellae. To identify which domains of DM-20 and PLP are isoforms. The 35 amino acid cytoplasmic peptide in PLP, which positioned topologically in the extracellular space to participate distinguishes this protein from DM-20, imparts a sensitivity to in adhesion, we engineered N-glycosylation consensus sites mutations in extracellular domains. This peptide may normally into the hydrophilic segments and determined the extent of function during myelinogenesis to detect conformational glycosylation. In addition, we assessed the presence of two changes originating across the bilayer from extracellular PLP translocation stop-transfer signals and, finally, mapped the interactions in trans and trigger intracellular events such as extracellular and cytoplasmic dispositions of four antibody membrane compaction in the cytoplasmic compartment. -
In Silico Perspectives on the Prediction of the PLP’S Epitopes Involved in Multiple Sclerosis
Iranian J Biotech. 2017 January;15(1):e1356 DOI: 10.15171/ijb.1356 Research Article In Silico Perspectives on the Prediction of the PLP’s Epitopes involved in Multiple Sclerosis Zahra Zamanzadeh1, Mitra Ataei1, Seyed Massood Nabavi2, Ghasem Ahangari1, Mehdi Sadeghi1, Mohammad Hosein Sanati1,* 1 Department of medical biotechnology. Institute of Medical Genetic, National Institute of Genetics Engineering and Biotechnology (NIGEB), Tehran, 14965/161 Iran 2 Department of Neurology, Faculty of Public Health, Shahed University, Tehran, 18155/159, Iran *Corresponding author: Department of Medical Genetic, National Institute of Genetic Engineering and Biotechnology (NIGEB), Shahrak-e- Pajoohesh, 15th Km, Tehran-Karaj Highway, Tehran, 14965-161, Iran. Tel.: +98 21 44780365; Fax: +98 21 44780395; E-mail: [email protected] Received: 15 Sep. 2015 Revised: 29 May 2016 Accepted: 13 March 2017 Published online: 31 May 2017 Background: Multiple sclerosis (MS) is the most common autoimmune disease of the central nervous system (CNS). The main cause of the MS is yet to be revealed, but the most probable theory is based on the molecular mimicry that concludes some infections in the activation of T cells against brain auto-antigens that initiate the disease cascade. Objectives: The Purpose of this research is the prediction of the auto-antigen potency of the myelin proteolipid protein (PLP) in multiple sclerosis. Materials and Methods: As there wasn’t any tertiary structure of PLP available in the Protein Data Bank (PDB) and in order to characterize the structural properties of the protein, we modeled this protein using prediction servers. Meta prediction method, as a new perspective in silico, was performed to fi nd PLPs epitopes. -
Genome-Wide DNA Methylation Analysis of KRAS Mutant Cell Lines Ben Yi Tew1,5, Joel K
www.nature.com/scientificreports OPEN Genome-wide DNA methylation analysis of KRAS mutant cell lines Ben Yi Tew1,5, Joel K. Durand2,5, Kirsten L. Bryant2, Tikvah K. Hayes2, Sen Peng3, Nhan L. Tran4, Gerald C. Gooden1, David N. Buckley1, Channing J. Der2, Albert S. Baldwin2 ✉ & Bodour Salhia1 ✉ Oncogenic RAS mutations are associated with DNA methylation changes that alter gene expression to drive cancer. Recent studies suggest that DNA methylation changes may be stochastic in nature, while other groups propose distinct signaling pathways responsible for aberrant methylation. Better understanding of DNA methylation events associated with oncogenic KRAS expression could enhance therapeutic approaches. Here we analyzed the basal CpG methylation of 11 KRAS-mutant and dependent pancreatic cancer cell lines and observed strikingly similar methylation patterns. KRAS knockdown resulted in unique methylation changes with limited overlap between each cell line. In KRAS-mutant Pa16C pancreatic cancer cells, while KRAS knockdown resulted in over 8,000 diferentially methylated (DM) CpGs, treatment with the ERK1/2-selective inhibitor SCH772984 showed less than 40 DM CpGs, suggesting that ERK is not a broadly active driver of KRAS-associated DNA methylation. KRAS G12V overexpression in an isogenic lung model reveals >50,600 DM CpGs compared to non-transformed controls. In lung and pancreatic cells, gene ontology analyses of DM promoters show an enrichment for genes involved in diferentiation and development. Taken all together, KRAS-mediated DNA methylation are stochastic and independent of canonical downstream efector signaling. These epigenetically altered genes associated with KRAS expression could represent potential therapeutic targets in KRAS-driven cancer. Activating KRAS mutations can be found in nearly 25 percent of all cancers1. -
1714 Gene Comprehensive Cancer Panel Enriched for Clinically Actionable Genes with Additional Biologically Relevant Genes 400-500X Average Coverage on Tumor
xO GENE PANEL 1714 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes 400-500x average coverage on tumor Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11 IL6R KAT5 ACVR2A -
Immunohistochemistry Stain Offerings
immunohistochemistry stain offerings TRUSTED PATHOLOGISTS. INVALUABLE ANSWERS.™ MARCHMAY 20172021 www.aruplab.com/ap-ihcaruplab.com/ap-ihc InformationInformation in this brochurein this brochure is current is current as of as May of March 2021. 2017. All content All content is subject is subject to tochange. change. Please contactPlease ARUPcontact ClientARUP Services Client Services at 800-522-2787 at (800) 522-2787 with any with questions any questions or concerns.or concerns. ARUP LABORATORIES As a nonprofit, academic institution of the University of Utah and its Department We believe in of Pathology, ARUP believes in collaborating, sharing and contributing to laboratory science in ways that benefit our clients and their patients. collaborating, Our test menu is one of the broadest in the industry, encompassing more sharing and than 3,000 tests, including highly specialized and esoteric assays. We offer comprehensive testing in the areas of genetics, molecular oncology, pediatrics, contributing pain management, and more. to laboratory ARUP’s clients include many of the nation’s university teaching hospitals and children’s hospitals, as well as multihospital groups, major commercial science in ways laboratories, and group purchasing organizations. We believe that healthcare should be delivered as close to the patient as possible, which is why we support that provide our clients’ efforts to be the principal healthcare provider in the communities they serve by offering highly complex assays and accompanying consultative support. the best value Offering analytics, consulting, and decision support services, ARUP provides for the patient. clients with the utilization management tools necessary to prosper in this time of value-based care. -
Notch Signalling Regulates Epibranchial Placode Patterning
Development | Peer review history Notch signalling regulates epibranchial placode patterning and segregation Li Wang, Junjie Xie, Haoran Zhang, Long Hin Tsang, Sze Lan Tsang, Eike-Benjamin Braune, Urban Lendahl and Mai Har Sham DOI: 10.1242/dev.183665 Editor: Francois Guillemot Review timeline Original submission: 16 August 2019 Editorial decision: 11 September 2019 First revision received: 24 December 2019 Accepted: 14 January 2020 Original submission First decision letter MS ID#: DEVELOP/2019/183665 MS TITLE: Notch signaling regulates epibranchial placode patterning, segregation and differentiation AUTHORS: Li Wang, Junjie Xie, Haoran Zhang, Long Hin Tsang, Sze Lan Tsang, Urban Lendahl, and Mai Har Sham I have now received the reports of three referees on your manuscript and I have reached a decision. The reports are appended below and you can access them online: please go to BenchPressand click on the 'Manuscripts with Decisions' queue in the Author Area. As you will see, all the referees express great interest in your work, but they also have some significant criticisms and recommend a substantial revision of your manuscript before we can consider publication. If you are able to revise the manuscript along the lines suggested, which may involve further experiments, I will be happy to receive a revised version of the manuscript. The identification of the Notch targets mentioned by referee 2 would be of course interesting but seems beyond the scope of the study unless you already have some evidence in that direction. The request of referee 3 that you analyse the effect of manipulations of Notch signalling at other stages than E9.5 will also require a significant amount of work without being necessarily informative. -
FUNCTIONAL ROLES for POST-TRANSLATIONAL MODIFICATIONS of T-SNARES in PLATELETS
University of Kentucky UKnowledge Theses and Dissertations--Molecular and Cellular Biochemistry Molecular and Cellular Biochemistry 2016 FUNCTIONAL ROLES FOR POST-TRANSLATIONAL MODIFICATIONS OF t-SNARES IN PLATELETS Jinchao Zhang University of Kentucky, [email protected] Digital Object Identifier: http://dx.doi.org/10.13023/ETD.2016.044 Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Zhang, Jinchao, "FUNCTIONAL ROLES FOR POST-TRANSLATIONAL MODIFICATIONS OF t-SNARES IN PLATELETS" (2016). Theses and Dissertations--Molecular and Cellular Biochemistry. 26. https://uknowledge.uky.edu/biochem_etds/26 This Doctoral Dissertation is brought to you for free and open access by the Molecular and Cellular Biochemistry at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Molecular and Cellular Biochemistry by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained needed written permission statement(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine) which will be submitted to UKnowledge as Additional File. I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and royalty-free license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known. -
Prdm13 Mediates the Balance of Inhibitory and Excitatory Neurons in Somatosensory Circuits
Developmental Cell Article Prdm13 Mediates the Balance of Inhibitory and Excitatory Neurons in Somatosensory Circuits Joshua C. Chang,1 David M. Meredith,1 Paul R. Mayer,1 Mark D. Borromeo,1 Helen C. Lai,1 Yi-Hung Ou,2 and Jane E. Johnson1,* 1Department of Neuroscience 2Department of Cell Biology UT Southwestern Medical Center, Dallas, TX 75390, USA *Correspondence: [email protected] http://dx.doi.org/10.1016/j.devcel.2013.02.015 SUMMARY genesis to generate the correct composition of neurons is critical. Here, we identify a key component of the transcriptional Generating a balanced network of inhibitory and machinery that controls how neurons in the somatosensory cir- excitatory neurons during development requires pre- cuit are generated and how regulated specification of these cise transcriptional control. In the dorsal spinal cord, neurons leads to a correct excitatory/inhibitory balance during Ptf1a, a basic helix-loop-helix (bHLH) transcription development. activator, maintains this delicate balance by inducing Excitatory and inhibitory neurons in the spinal cord arise from homeodomain (HD) transcription factors such as progenitor populations within the ventricular zone of the dorsal neural tube (Gross et al., 2002; Mu¨ ller et al., 2002). These pro- Pax2 to specify the inhibitory lineage while suppress- genitors are competent to give rise to neurons in either class ing HD factors such as Tlx1/3 that specify the excit- depending on the basic helix-loop-helix (bHLH) transcription fac- atory lineage. We uncover the mechanism by which tors that are expressed (Helms and Johnson, 2003; Zhuang and Ptf1a represses excitatory cell fate in the inhibitory Sockanathan, 2006). -
The Tumor Suppressor HHEX Inhibits Axon Growth When Prematurely Expressed in Developing Central Nervous System Neurons
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by epublications@Marquette Marquette University e-Publications@Marquette Biological Sciences Faculty Research and Biological Sciences, Department of Publications 9-1-2015 The umorT Suppressor HHEX Inhibits Axon Growth when Prematurely Expressed in Developing Central Nervous System Neurons Matthew .T Simpson Marquette University Ishwariya Venkatesh Marquette University Ben L. Callif Marquette University Laura K. Thiel Marquette University Denise M. Coley Marquette University See next page for additional authors Accepted version. Molecular and Cellular Neuroscience, Vol 68 )September 2015): 272-283. DOI. © 2015 Elsevier Inc. Used with permission. NOTICE: this is the author’s version of a work that was accepted for publication in Molecular and Cellular Neuroscience. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Molecular and Cellular Neuroscience, Vol 68 )September 2015): 272-283. DOI. Authors Matthew T. Simpson, Ishwariya Venkatesh, Ben L. Callif, Laura K. Thiel, Denise M. Coley, Kristen N. Winsor, Zimei Wang, Audra A. Kramer, Jessica K. Lerch, and Murray G. Blackmore This article is available at e-Publications@Marquette: https://epublications.marquette.edu/bio_fac/515 NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be accessed by following the link in the citation at the bottom of the page. The Tumor Suppressor HHEX Inhibits Axon Growth When Prematurely Expressed in Developing Central Nervous System Neurons Matthew T. -
In Silico Perspectives on the Prediction of the PLP's
Iranian J Biotech. 2017 January;15(1):e1356 DOI: 10.15171/ijb.1356 Research Article In Silico Perspectives on the Prediction of the PLP’s Epitopes involved in Multiple Sclerosis Zahra Zamanzadeh1, Mitra Ataei1, Seyed Massood Nabavi2, Ghasem Ahangari1, Mehdi Sadeghi1, Mohammad Hosein Sanati1,* 1 Department of medical biotechnology. Institute of Medical Genetic, National Institute of Genetics Engineering and Biotechnology (NIGEB), Tehran, 14965/161 Iran 2 Department of Neurology, Faculty of Public Health, Shahed University, Tehran, 18155/159, Iran *Corresponding author: Department of Medical Genetic, National Institute of Genetic Engineering and Biotechnology (NIGEB), Shahrak-e- Pajoohesh, 15th Km, Tehran-Karaj Highway, Tehran, 14965-161, Iran. Tel.: +98 21 44780365; Fax: +98 21 44780395; E-mail: [email protected] Received: 15 Sep. 2015 Revised: 29 May 2016 Accepted: 13 March 2017 Published online: 31 May 2017 Background: Multiple sclerosis (MS) is the most common autoimmune disease of the central nervous system (CNS). The main cause of the MS is yet to be revealed, but the most probable theory is based on the molecular mimicry that concludes some infections in the activation of T cells against brain auto-antigens that initiate the disease cascade. Objectives: The Purpose of this research is the prediction of the auto-antigen potency of the myelin proteolipid protein (PLP) in multiple sclerosis. Materials and Methods: As there wasn’t any tertiary structure of PLP available in the Protein Data Bank (PDB) and in order to characterize the structural properties of the protein, we modeled this protein using prediction servers. Meta prediction method, as a new perspective in silico, was performed to fi nd PLPs epitopes. -
Deregulation of the HOXA10 Homeobox Gene in Endometrial Carcinoma: Role in Epithelial-Mesenchymal Transition
Research Article Deregulation of the HOXA10 Homeobox Gene in Endometrial Carcinoma: Role in Epithelial-Mesenchymal Transition Hiroyuki Yoshida,1 Russell Broaddus,2 Wenjun Cheng,1 SuSu Xie,2 and Honami Naora1 Departments of 1Molecular Therapeutics and 2Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas Abstract normally expressed during early urogenital development, and is expressed in renal tumors (6). PAX2 is thought to promote cell Homeobox genes encode transcription factors that control cell survival, and inhibiting PAX2 expression in cancer cells induces differentiation and play essential roles in developmental apoptosis (7). On the other hand, many homeobox genes that are patterning. Increasing evidence indicates that many homeo- normally expressed in differentiated tissues are lost or down- box genes are aberrantly expressed in cancers, and that their regulated in tumors. Nkx3.1 controls prostate morphogenesis and deregulation significantly contributes to tumor progression. is normally expressed in the prostate during development and in The homeobox gene HOXA10 controls uterine organogenesis the adult (8). NKX3.1 is frequently deleted in prostate cancers (9), during embryonic development and functional endometrial and enforced expression of NKX3.1 in prostate cancer cells differentiation in the adult. We investigated whether HOXA10 inhibits cell growth (10). Many other homeobox genes contribute expression is deregulated in endometrial carcinomas, and to tumor progression by promoting cell growth and/or survival how counteracting this aberrant expression modifies tumor (4, 5). However, given the important role of homeobox genes in behavior. We found that down-regulation of HOXA10 expres- cell differentiation, surprisingly little is known regarding their role sion in endometrial carcinomas strongly correlates with in EMT.